|
gptkbp:instance_of
|
gptkb:stock_market_index
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Tandem_Diabetes_Care
|
|
gptkbp:acquisition
|
Acquired by Tandem Diabetes Care, Inc.
|
|
gptkbp:awards
|
gptkb:Red_Dot_Design_Award
Best in KLAS for Insulin Delivery
|
|
gptkbp:capacity
|
Average 1 million shares per day
|
|
gptkbp:ceo
|
gptkb:John_Sheridan
|
|
gptkbp:clinical_trial
|
Ongoing clinical trials for new products
|
|
gptkbp:community_engagement
|
Engages with diabetes community
|
|
gptkbp:community_support
|
Supports diabetes education initiatives
|
|
gptkbp:competitors
|
gptkb:Insulet_Corporation
gptkb:Roche
gptkb:Medtronic
|
|
gptkbp:customer_base
|
Healthcare providers
Patients with Type 1 Diabetes
|
|
gptkbp:dividend_yield
|
No dividends paid
|
|
gptkbp:employees
|
Approximately 800
|
|
gptkbp:financial_performance
|
Quarterly financial reports available
|
|
gptkbp:financial_products
|
gptkb:Company
|
|
gptkbp:focus
|
Diabetes management
|
|
gptkbp:founded
|
gptkb:2006
|
|
gptkbp:future_plans
|
Expansion of product line
International market expansion
|
|
gptkbp:headquarters
|
gptkb:San_Diego,_California
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TNDM
|
|
gptkbp:industry
|
gptkb:hospital
|
|
gptkbp:invention
|
Multiple patents in insulin delivery technology
|
|
gptkbp:investment
|
Annual shareholder meetings
Volatile stock performance
Institutional investors hold significant shares
|
|
gptkbp:ipo
|
gptkb:2013
|
|
gptkbp:is_divided_into
|
Stock split in 2018
|
|
gptkbp:market_cap
|
Approximately $1.5 billion
|
|
gptkbp:part_of
|
gptkb:S&_P_600
|
|
gptkbp:partnerships
|
Partnership with Abbott
Partnership with Dexcom
|
|
gptkbp:population_trend
|
Growing market for diabetes technology
|
|
gptkbp:production_company
|
gptkb:Tandem_Diabetes_Care,_Inc.
|
|
gptkbp:products
|
gptkb:Control-IQ_Technology
gptkb:t:slim_Insulin_Delivery_System
gptkb:t:slim_X2_Insulin_Delivery_System
|
|
gptkbp:rating
|
Generally positive analyst ratings
|
|
gptkbp:research_and_development
|
Significant investment in R& D
|
|
gptkbp:revenue
|
Approximately $300 million (2022)
|
|
gptkbp:social_media
|
Active on social media platforms
|
|
gptkbp:sustainability
|
Focus on sustainable practices
|
|
gptkbp:symbol
|
gptkb:TNDM
|
|
gptkbp:technology
|
gptkb:Continuous_Glucose_Monitoring_(CGM)
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.tandemdiabetes.com
|